Progenics Pharma Revenue, Profits - PGNX Annual Income Statement

Add to My Stocks
$8.47 $0.16 (1.85%) PGNX stock closing price Jun 21, 2018 (Closing)

PGNX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Progenics Pharma stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 69.42M to 11.69M and how operating and non operating activities have impacted the PGNX stock. The operating expenses as shown in the Progenics Pharma profit and loss statement for 2017 total to $70.08M. This line item shows that the operating expenses has increased compared with last year. Also check: Progenics Pharma assets and Progenics Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Progenics Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Progenics Pharma Gross Profit
Research & Development Expense42.58M37.56M28.19M28.59M35.09M33.5M54.16M52.15M51.09M85.13M
Selling General & Admin Expense27.5M18.75M19.78M9.19M14.8M14.7M18.24M22.83M25.1M28.83M
Income Before Depreciation Depletion Amortization-58.4M13.1M-39.3M6.59M-42.04M-34.16M12.38M-67.03M-27.25M-46.29M
Depreciation Depletion Amortization---3.22M-1.32M2.06M2.85M5.07M4.6M
Non Operating Income-4.28M-0.03M------1.71M6.23M
Interest Expense----------
Progenics Pharma Pretax Income
Provision for Income Taxes-11.67M1.84M-0.13M-0.98M-0.36M---0.09M--
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-51.01M10.73M-39.11M4.41M-42.57M-35.43M10.38M-69.72M-30.61M-44.67M
Extraordinary Items & Discontinued Operations----------
Progenics Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS70.28M70.16M69.72M68.24M55.8M34.75M33.49M32.59M31.22M29.65M
Average Shares used to compute Basic EPS70.28M70M69.72M68.19M55.8M34.75M33.38M32.59M31.22M29.65M
Income Before Nonrecurring Items-62.71M10.81M-39.11M4.41M-42.57M-35.43M10.38M-69.73M-30.85M-44.67M
Income from Nonrecurring Items11.7M---------
Progenics Pharma Earnings Per Share Basic Net
Progenics Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.900.15-0.560.06-0.76-1.020.31-2.14-0.99-1.51
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Progenics Pharma stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Progenics Pharma revenue chart implies that the company is growing. It has not been the case with Progenics Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-51.01M for Progenics Pharma for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the PGNX income statement, one can check the Progenics Pharma historical stock prices to check how the price has moved with time.

Progenics Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield